Litcius/Paper detail

Laboratory-Confirmed COVID-19–Associated Hospitalizations Among Adults During SARS-CoV-2 Omicron BA.2 Variant Predominance — COVID-19–Associated Hospitalization Surveillance Network, 14 States, June 20, 2021–May 31, 2022

Fiona P. Havers, Kadam Patel, Michael Whitaker, Jennifer Milucky, Arthur Reingold, Isaac Armistead, James Meek, Evan J. Anderson, Andy Weigel, Libby Reeg, Scott Seys, Susan L. Ropp, Nancy Spina, Christina B. Felsen, Nancy E Moran, Melissa Sutton, H. Keipp Talbot, Andrea George, Christopher A. Taylor, COVID-NET Surveillance Team, COVID-NET Surveillance Team, Pam Daily Kirley, Nisha B. Alden, Kimberly Yousey‐Hindes, Kyle P. Openo, Chloë Brown, Cody Schardin, Kelly Plymesser, Grant Barney, Kevin Popham, Laurie M. Billing, Nasreen Abdullah, Tiffanie Markus, Mary Hill

2022MMWR Morbidity and Mortality Weekly Report33 citationsDOIOpen Access PDF

Abstract

Beginning the week of March 20–26, 2022, the Omicron BA.2 variant of SARS-CoV-2, the virus that causes COVID-19, became the predominant circulating variant in the United States, accounting for >50% of sequenced isolates.* Data from the COVID-19–Associated Hospitalization Surveillance Network (COVID-NET) were analyzed to describe recent COVID-19–associated hospitalization rates among adults aged ≥18 years during the period coinciding with BA.2 predominance (BA.2 period [Omicron BA.2 and BA.2.12.1; March 20–May 31, 2022]). Weekly hospitalization rates (hospitalizations per 100,000 population) among adults aged ≥65 years increased threefold, from 6.9 (week ending April 2, 2022) to 27.6 (week ending May 28, 2022); hospitalization rates in adults aged 18–49 and 50–64 years both increased 1.7-fold during the same time interval. Hospitalization rates among unvaccinated adults were 3.4 times as high as those among vaccinated adults. Among hospitalized nonpregnant patients in this same period, 39.1% had received a primary vaccination series and 1 booster or additional dose; 5.0% had received a primary series and ≥2 boosters or additional doses. All adults should stay up to date† with COVID-19 vaccination, and multiple nonpharmaceutical and medical prevention measures should be used to protect those at high risk for severe COVID-19 illness, irrespective of vaccination status§ (1). Beginning the week of March 20–26, 2022, the Omicron BA.2 variant of SARS-CoV-2, the virus that causes COVID-19, became the predominant circulating variant in the United States, accounting for >50% of sequenced isolates.* Data from the COVID-19–Associated Hospitalization Surveillance Network (COVID-NET) were analyzed to describe recent COVID-19–associated hospitalization rates among adults aged ≥18 years during the period coinciding with BA.2 predominance (BA.2 period [Omicron BA.2 and BA.2.12.1; March 20–May 31, 2022]). Weekly hospitalization rates (hospitalizations per 100,000 population) among adults aged ≥65 years increased threefold, from 6.9 (week ending April 2, 2022) to 27.6 (week ending May 28, 2022); hospitalization rates in adults aged 18–49 and 50–64 years both increased 1.7-fold during the same time interval. Hospitalization rates among unvaccinated adults were 3.4 times as high as those among vaccinated adults. Among hospitalized nonpregnant patients in this same period, 39.1% had received a primary vaccination series and 1 booster or additional dose; 5.0% had received a primary series and ≥2 boosters or additional doses. All adults should stay up to date† with COVID-19 vaccination, and multiple nonpharmaceutical and medical prevention measures should be used to protect those at high risk for severe COVID-19 illness, irrespective of vaccination status§ (1).

Topics & Concepts

MedicineCoronavirus disease 2019 (COVID-19)VaccinationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Young adultPediatricsPopulation2019-20 coronavirus outbreakEmergency medicineDemographyInternal medicineVirologyDiseaseOutbreakInfectious disease (medical specialty)Environmental healthSociologySARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19